In the present retrospective study, we demonstrate, for the first time, that in colorectal adenomas the combined evaluation of global genomic and intragenic hypomethylation, analyzed by LINE-1 and L1-MET assays, could be used as a potential molecular marker to improve the classification of patients for their CRC risk. This evidence concerns the gene MET and colorectal adenoma.